Tepmetko

Active Ingredient(s): Tepotinib Hydrochloride
FDA Approved: * February 3, 2021
Pharm Company: * EMD SERONO INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tepmetko Overview

Tepotinib, sold under the brand name Tepmetko, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.[1][2][3] It is a c-Met inhibitor, a type of tyrosine kinase inhibitor. Tepotinib first received marketing approval in Japan, in March 2020, as a "line-agnostic" drug, meaning it is approved both for treatm...

Read more Tepmetko Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tepotinib

Recent Tepmetko Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Tepmetko: (1 result)

Sorted by National Drug Code

• 44087-5000 Tepmetko 225 mg Oral Tablet by Emd Serono, Inc.

Other drugs which contain Tepotinib Hydrochloride or a similar ingredient: (1 result)

• TEPOTINIB